exciting preliminary results of m6620 combination therapy for triple negative breast cancer
Published 6 years ago • 360 plays • Length 4:30Download video MP4
Download video MP3
Similar videos
-
2:46
de-escalation of therapy in early-stage tnbc
-
2:09
triplet combination of chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
1:58
promising novel approaches to the treatment of tnbc
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
2:47
current treatment landscape of triple negative breast cancer
-
1:38
combined analyses of pd-l1 and tils for therapy selection in tnbc
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
2:30
impassion130: immunotherapy for tnbc
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
1:15
clinical implications of progress in tnbc therapies
-
1:29
lig1 deletion predicts chemotherapy resistance in triple-negative breast cancer
-
2:14
javelin parp medley: combining parp inhibitors and immune checkpoint inhibitors
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
0:41
recent advances in targeted therapies for tnbc
-
1:30
begonia: durvalumab combinations in advanced tnbc
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
1:04
are combination approaches the way forward for treating patients with triple-negative breast cancer?
-
1:45
targeting egfr for the treatment of inflammatory breast cancer